^
Association details:
| Biomarker: | LAG3 expression + CTAG1B expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
Published date:
01/17/2021
Excerpt:
Patients with both NY-ESO-1- and LAG-3-expressing tumors had a high DCB rate...LAG-3 and NY-ESO-1 co-expression was an independent predictor of both PFS and OS...NY-ESO-1 and LAG-3 could be novel predictive biomarkers of survival and should be considered in the future use of ICIs.
DOI:
10.1111/1759-7714.13834
